
    
      This is a Phase 1/2, multicenter, open-label study in subject with DME associated with
      diabetes mellitus.

      Subjects will be screened and if eligible, will be assigned to study arm at the Baseline
      Visit (Visit 1, Day 0).

      Following the Baseline Visit, subjects will participate in six monthly follow-up visits
      (Visit 2-7; Weeks 4-24) for safety and efficacy assessments and to determine whether
      additional therapy is needed based upon pre-defined criteria.
    
  